<DOC>
	<DOC>NCT00116116</DOC>
	<brief_summary>The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.</brief_summary>
	<brief_title>DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients 18 years of age or older infected with HIV and weigh at least 40 kg. Plasma HIV RNA viral load of 1000 copies/mL or greater and CD4 count of 100 cells/mL or greater. Be willing to use two forms of contraception throughout study. No previous exposure to antiretroviral (ARV) drugs Pregnancy or breastfeeding Physical or psychiatric disability Proven or suspected acute hepatitis within 30 days prior to study entry Active AIDSdefining opportunistic infection or disease History of acute or chronic pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV/AIDS</keyword>
</DOC>